The 50% difference in Psp occurrence between the two groups (91% vs. 41%) reinforces the clinical relevance of this finding, suggesting that MGMT methylation status may be a good predictor of Psp in treated GBM patients. This evidence concerns the gene MGMT and glioblastoma.